James analyst Dane Leone maintained a Strong Buy rating and a $19.00 price target on Ocular Therapeutix (NASDAQ:OCUL), aligning with the broader analyst consensus. According to InvestingPro data, ...
BEDFORD, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced upcoming ...
EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...
The 1-year results from the HELIOS Trial that evaluated the investigational intravitreal AXPAXLI implant (OTX-TKI, Ocular Therapeutix) for the treatment of non-proliferative diabetic retinopathy (NPDR ...
Ocular Therapeutix (OCUL) plans to advance AXPAXLI in non-proliferative diabetic retinopathy, NPDR, and the Company’s strategic outlook for 2025 in its presentation at the 43rd Annual J.P ...
outlined exceptional clinical progress across its registrational program for AXPAXLI™ in wet age-related macular degeneration (wet AMD), plans to advance AXPAXLI in non-proliferative diabetic ...
Diabetic retinopathy is a common complication in people with type 1 and type 2 diabetes, progressing from mild, moderate, and severe non-proliferative diabetic retinopathy to proliferative diabetic ...
ABBV-RGX-314 in Diabetic Retinopathy (DR), Suprachoroidal Delivery AbbVie and REGENXBIO will plan a Phase 3 clinical program. The clinical program will utilize the in-office SCS Microinjector ...
“Together with AbbVie, we are excited to continue developing ABBV-RGX-314 as the first potential one-time gene therapy for wet AMD and DR.” ABBV-RGX-314 is being investigated as a potential one-time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback